News
Is Merck Stock a Buy Now?
Merck (NYSE: MRK) has performed poorly in the stock market this year, with the drugmaker's shares down by 5%. But zooming out helps put a different spin on this story as the pharmaceutical giant has
3 Top Biotech Stocks Defying the Bear Market
If you look at the S&P 500, which is up more than 18% this year, or the Nasdaq Composite, which is up more than 34% in 2023, it appears the markets are booming. If you look specifically at biotech
EQS-News: Biotest AG: Biotest increases EBIT to Euro 19.8 million in the first half of 2023
MacroGenics (MGNX) Q2 2023 Earnings Call Transcript
Image source: The Motley Fool.
MacroGenics (NASDAQ: MGNX)Q2 2023 Earnings CallAug 09, 2023, 4:30 p.m. ET
Operator
Source Fool.com
Why 23andMe Holding Stock Plummeted by 13% Today
Genetic-testing company and researcher 23andMe Holding (NASDAQ: ME) wasn't testing very well with investors on Wednesday. They assertively sold out of the company's shares, to the point where the
2 Supercharged Growth Stocks That Could Make You Richer
If you're looking for stocks that can deliver better-than-average returns in the long run, you might want to consider these two biotechs: Exact Sciences (NASDAQ: EXAS) and Vertex Pharmaceuticals
EQS-News: MorphoSys AG Reports Second Quarter and First Half 2023 Financial Results
Why Shares of BioLife Solutions Are Slumping on Wednesday
Shares of BioLife Solutions (NASDAQ: BLFS) were down by more than 27% as of 1:15 p.m. on Wednesday after the healthcare company posted its second-quarter earnings report. The stock is down more than
Why Shares of Mirati Therapeutics Are Jumping Wednesday
Shares of Mirati Therapeutics (NASDAQ: MRTX) are up more than 27% as of 10:25 a.m. ET. The company released earnings after the markets closed on Tuesday. The healthcare stock is down more than 21%
3 Stocks That Recently Raised Their Guidance for the Year
GDP grew at a rate of 2.4% in the second quarter as the economy did better than expected. And many businesses are also seeing strong demand for their products and services. That, in turn, leads to
More Alzheimer's Treatments Are Coming: This Company Can Help With Early Detection
Alzheimer's patients could soon have more treatment options available. Biogen's Leqembi obtained approval from the U.S. Food and Drug Administration earlier this year, and another treatment from Eli
Pfizer's Profits Plunge 77%: Is the Dividend Still Safe?
Pfizer (NYSE: PFE) provides investors with an attractive dividend that currently yields 4.7%. To collect $1,000 in annual dividends at that rate, you would need to invest approximately $21,300
Is Viatris Stock Good for Dividend Income?
Viatris (NASDAQ: VTRS) is a stock of immense interest among the dividend investing community, and it's no surprise why. Generic drugmakers, when operating smoothly, can be veritable cash machines
With an Acquisition on the Way, Is Biogen Stock a Buy?
Biotech giant Biogen (NASDAQ: BIIB) can't seem to keep its name out of the news. After a recent major approval for its Alzheimer's disease (AD) medicine Leqembi, the company just announced that it
Opinion: These Will Be the 5 Biggest Stocks by 2030
Only seven years ago, AT&T and General Electric were the eighth- and ninth-largest American companies by market cap, respectively. Today, AT&T has fallen to 81st, while General Electric is 65th. A
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Is Vertex Pharmaceuticals Stock a Buy Now?
As one of the hottest and most-watched companies in the biopharmaceutical sector, Vertex Pharmaceuticals (NASDAQ: VRTX) has a unique mix of stability and growth potential that's attractive to a
Invitae (NVTA) Q2 2023 Earnings Call Transcript
Image source: The Motley Fool.
Invitae (NYSE: NVTA)Q2 2023 Earnings CallAug 08, 2023, 4:30 p.m. ET
Operator
Source Fool.com
Why MannKind Stock Soared 19% Higher on Tuesday
Commercial-stage biotech MannKind (NASDAQ: MNKD) was a top choice of investors on the second day of the trading week. Tuesday saw MannKind's share price leap by almost 19%, making it stand out on a
CorMedix (CRMD) Q2 2023 Earnings Call Transcript
Image source: The Motley Fool.
CorMedix (NASDAQ: CRMD)Q2 2023 Earnings CallAug 08, 2023, 8:30 a.m. ET
Operator
Source Fool.com
Why Novocure Was a Healthy Stock Today
Cancer-focused biotech Novocure (NASDAQ: NVCR) was the focus of an analyst upgrade on Tuesday, and the stock benefited from the move. In late-session trading that day, it was up by more than 3.3% in
Zoetis (ZTS) Q2 2023 Earnings Call Transcript
Image source: The Motley Fool.
Zoetis (NYSE: ZTS)Q2 2023 Earnings CallAug 08, 2023, 8:30 a.m. ET
Operator
Source Fool.com
Why Shares of Enanta Pharmaceuticals Are Dropping Tuesday
Shares of Enanta Pharmaceuticals (NASDAQ: ENTA) were down more than 9% as of 11:45 a.m. on Tuesday after the clinical-stage biotech released fiscal third-quarter earnings on Tuesday. The stock is
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Are On Fire Today
Weight loss drugmakers are having an exceptionally strong trading session today. As of 10:32 a.m. ET Tuesday morning, Eli Lilly (NYSE: LLY) was up by a noteworthy 16.7%, Novo Nordisk (NYSE: NVO) was
Is Sage Therapeutics a Contrarian Buy?
Monday was a dark day for Sage Therapeutics (NASDAQ: SAGE), a company that focuses on developing therapies for brain disorders. The stock plummeted by more than 53% after the company revealed that